About the Authors
- Julian Krauskopf
-
* E-mail: j.krauskopf@maastrichtuniversity.nl
Affiliation Department of Toxicogenomics, Maastricht University, Maastricht, the Netherlands
- Theo M. de Kok
-
Affiliation Department of Toxicogenomics, Maastricht University, Maastricht, the Netherlands
- Shelli J. Schomaker
-
Affiliation Drug Safety Research and Development, Pfizer Inc., Groton, Connecticut, United States of America
- Mark Gosink
-
Affiliation Drug Safety Research and Development, Pfizer Inc., Groton, Connecticut, United States of America
- Deborah A. Burt
-
Affiliation Drug Safety Research and Development, Pfizer Inc., Groton, Connecticut, United States of America
- Patricia Chandler
-
Affiliation Clinical Research Unit, Pfizer Inc., New Haven, Connecticut, United States of America
- Roscoe L. Warner
-
Affiliation Pathology Department, University of Michigan, Ann Arbor, Michigan, United States of America
- Kent J. Johnson
-
Affiliation Pathology Department, University of Michigan, Ann Arbor, Michigan, United States of America
- Florian Caiment
-
Affiliation Department of Toxicogenomics, Maastricht University, Maastricht, the Netherlands
- Jos C. Kleinjans
-
Affiliation Department of Toxicogenomics, Maastricht University, Maastricht, the Netherlands
- Jiri Aubrecht
-
Affiliation Drug Safety Research and Development, Pfizer Inc., Groton, Connecticut, United States of America
Competing Interests
We have the following interests: Shelli J. Schomaker, Mark Gosink, Deborah A. Burt, Patricia Chandler and Jiri Aubrecht are employed by Pfizer Inc. The project was funded by Pfizer Inc. in forms of research grants to J.C.K. (University of Maastricht) and K.J.J. (University of Michigan). There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceptualization: JK TMK SJS RLW KJJ FC JCK JA. Data curation: SJS PC RLW KJJ. Formal analysis: JK FC DAB MG. Funding acquisition: JA. Investigation: JK DAB MG JA. Methodology: JK MG JA. Project administration: TMK JCK JA. Resources: TMK JCK SJS PC RLW KJJ. Software: JK FC MG. Supervision: TMK JCK JA. Validation: TMK JCK JA. Visualization: JK TMK JCK JA. Writing – original draft: JK TMK JCK JA. Writing – review & editing: JK TMK SJS MG DAB PC RLW KJJ FC JCK JA.